Moomoo AIのまとめ
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmaceuticals, Inc. has filed a prospectus related to the resale of up to 2,369,000 shares of common stock by Selling Stockholders. The shares are associated with Series C Common Warrants and Placement Agent Warrants issued in a private placement transaction that closed on March 6, 2024. The Selling Stockholders include certain identified stockholders and designees of H.C. Wainwright & Co., LLC, the placement agent for the private placement. The registration of these shares does not necessarily mean that the Selling Stockholders will sell their stock, as the sale is at their discretion. Adial Pharmaceuticals will not offer any shares under this prospectus and will not receive proceeds from the sale of the shares by the Selling Stockholders. However, the company will receive proceeds from any cash exercise of the warrants. The common stock is listed on the Nasdaq Capital Market under the symbol 'ADIL.' As of April 10, 2024, the closing price of Adial's common stock was $2.33 per share. The date of the prospectus is April 19, 2024.
Adial Pharmaceuticalsは、Selling Stockholdersによって最大2,369,000株の普通株式が転売可能になることに関する目論見書を提出しました。これらの株式は、2024年3月6日に終了した非公募発行取引で発行されたSeries C Common WarrantsおよびPlacement Agent Warrantsに関連しています。Selling Stockholdersには、H.C. Wainwright & Co.、LLCのプレースメント・エージェントおよび指定された株主が含まれています。これらの株式の登録があっても、Selling Stockholde...すべて展開
Adial Pharmaceuticalsは、Selling Stockholdersによって最大2,369,000株の普通株式が転売可能になることに関する目論見書を提出しました。これらの株式は、2024年3月6日に終了した非公募発行取引で発行されたSeries C Common WarrantsおよびPlacement Agent Warrantsに関連しています。Selling Stockholdersには、H.C. Wainwright & Co.、LLCのプレースメント・エージェントおよび指定された株主が含まれています。これらの株式の登録があっても、Selling Stockholdersが株式を売却する必要はなく、売却は彼らの裁量に委ねられます。Adial Pharmaceuticalsは、この目論見書の下で株式を提供せず、Selling Stockholdersによる株式の売却から得られる収益についても受け取りません。ただし、現金行使によるワラントの収益については受け取ります。Adialの普通株式は、Nasdaq Capital Marketにシンボル'ADIL'で上場されています。2024年4月10日時点で、Adialの普通株式の終値は株式1株あたり2.33ドルでした。この目論見書の日付は2024年4月19日です。
役に立った
役に立たない